EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Haemostatic effects of erythropoietin treatment with and without acetylsalicylic acid in individuals with chronic kidney disease: a prospective single-arm repeated-measures study

Mette Koefoed, James Heaf, Rune Larsen, Erik Lerkevang Grove, Julie Brogaard Larsen, Rikke Borg

Clinical Kidney Journal · 10.11.2026

DOI: 10.1093/ckj/sfag398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 10.11.2026. Verfasst von Mette Koefoed und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Erythropoiesis-stimulating agents (ESAs) are used to treat anemia in chronic kidney disease (CKD). ESAs have been associated with increased thrombotic risk, but the underlying mechanisms remain unclear. Given its antiplatelet effects and widespread use in cardiovascular prevention, we hypothesized that concomitant acetylsalicylic acid (ASA) attenuates ESA-induced prothrombotic alterations in hemostasis in patients with CKD.

Methods

We conducted a prospective single-arm, repeated-measures, interventional phase 4 study in 27 individuals with advanced CKD (hemodialysis, peritoneal dialysis, and non-dialysis). The study comprised four consecutive 4-week phases: ESA washout, ESA treatment, ESA plus ASA (75 mg daily), and post-treatment washout. At the end of each phase, we assessed platelet function, whole-blood coagulation, endothelial activation, coagulation activation, and fibrinolysis.

Results

ESA treatment induced a modest and reversible increase in platelet count, whereas markers of immature platelets (IPF and H-IPF) decreased. Soluble P-selectin increased slightly during ESA treatment, indicating mild platelet and/or endothelial activation. Platelet aggregation, thromboelastometry parameters, prothrombin fragment 1 + 2, fibrin D-dimer, soluble thrombomodulin, and fibrinolysis markers remained largely unchanged throughout ESA treatment and ASA had no effect on ESA-related changes.

Conclusions

In individuals with advanced CKD, short-term ESA treatment was associated with modest changes in platelet count and soluble P-selectin but did not result in measurable changes in platelet function, coagulation activity or fibrinolysis. ASA did not modify ESA-related effects and did not induce measurable haemostatic changes. These findings do not support a major systemic procoagulant effect of ESA, indicating that alternative mechanisms might contribute to the increased thrombotic risk observed in clinical trials.

Zitieren

APA

Koefoed, M., Heaf, J., Larsen, R., Grove, E. L., Larsen, J. B., & Borg, R. (2026). Haemostatic effects of erythropoietin treatment with and without acetylsalicylic acid in individuals with chronic kidney disease: a prospective single-arm repeated-measures study. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfag398

Vancouver

Koefoed M, Heaf J, Larsen R, Grove EL, Larsen JB, Borg R. Haemostatic effects of erythropoietin treatment with and without acetylsalicylic acid in individuals with chronic kidney disease: a prospective single-arm repeated-measures study. Clinical Kidney Journal. 2026. doi:10.1093/ckj/sfag398

BibTeX
@article{Koefoed2026,
  author = {Koefoed, Mette and Heaf, James and Larsen, Rune and Grove, Erik Lerkevang and Larsen, Julie Brogaard and Borg, Rikke},
  title = {Haemostatic effects of erythropoietin treatment with and without acetylsalicylic acid in individuals with chronic kidney disease: a prospective single-arm repeated-measures study},
  journal = {Clinical Kidney Journal},
  year = {2026},
  doi = {10.1093/ckj/sfag398}
}
Kostenlos starten →